CVS Health Corp (NY:CVS)

86.46 +1.26 (+1.48%)

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CVS Health Corp

< Previous 1 2 3 4 5 6 7 8 9

...

72 73 Next >

Tuesday's pre-market session: top gainers and losers in the S&P500 index ↗

January 27, 2026

Via Chartmill

Nasdaq, S&P 500 Futures Climb As Investors Brace For Earnings Rush, Fed Signals: Why META, MSFT, MU, UNH, GME Are On Traders' Radar Today ↗

January 27, 2026

Retail sentiment around major ETFs such as SPY and QQQ stayed bearish on Stocktwits.

Via Stocktwits

Topics ETFs Economy Government

UNH, HUM, Other Health Insurer Stocks Could Take Time To Recover From Medicare Rate Shock: Cantor Fitzgerald ↗

January 27, 2026

CMS’s plan to keep Medicare Advantage payments nearly flat for 2027 blindsided investors and sparked a sharp selloff across U.S. health insurers.

Via Stocktwits

Topics Initial Public Offering

Dow, S&P 500, Nasdaq Futures Mixed As Investors Brace For More Big Tech Earnings, Fed Policy Update ↗

January 27, 2026

Via Stocktwits

Topics Economy Stocks

Discover the top S&P500 movers in Monday's after-hours session. ↗

January 26, 2026

Via Chartmill

CVS Health Corp (NYSE:CVS) Shows Top Technical Rating and Superior Setup for Potential Breakout ↗

January 14, 2026

Via Chartmill

UNH, HUM, CVS Shares Fall On Plans To Keep Medicare Payments Flat Next Year ↗

January 26, 2026

CMS said that the proposed policies are projected to result in a net average year-over-year payment increase of 0.09% for Medicare Advantage plans in CY 2027.

Via Stocktwits

2 Dirt Cheap Stocks to Buy With $200 Right Now ↗

January 24, 2026

These healthcare leaders seem attractive right now.

Via The Motley Fool

Topics Artificial Intelligence

Should You Buy CVS Health Stock Before Feb. 10? ↗

January 21, 2026

The diversified healthcare company reports earnings next month.

Via The Motley Fool

J&J Forecasts $100 Billion Milestone for 2026 as Trump Drug Pricing Deals Reshape the Pharma Landscape

January 21, 2026

NEW BRUNSWICK, N.J. — In a landmark display of resilience and strategic pivoting, Johnson & Johnson (NYSE: JNJ) reported fourth-quarter 2025 revenues of $24.56 billion on Wednesday, January 21, 2026,...

Via MarketMinute

Topics Earnings Economy Government

3 Value Stocks with Warning Signs

January 19, 2026

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are...

Via StockStory

The Policy Tug-of-War: 2026 Market Outlook Targets 12% Growth Amid Fed Pivot and Tariff Shocks

January 16, 2026

As of January 16, 2026, the financial markets are navigating a complex "policy-driven tug-of-war" that has set the stage for a volatile yet potentially lucrative year. Investors are balancing the...

Via MarketMinute

Topics Artificial Intelligence Economy Government

UNH, CI, CVS Stocks Rise After Trump Unveils ‘Great Healthcare Plan’ ↗

January 15, 2026

Under President Trump’s ‘Great Healthcare Plan,’ money will directly be delivered to people to purchase their healthcare.

Via Stocktwits

Topics Government

Trade Tensions and Price Tags: 2026 Inflation Fears Surge as Tariff Costs Loom Over Global Markets

January 13, 2026

As of mid-January 2026, the global financial markets are caught in a tense "wait-and-see" pattern. Investors are increasingly jittery as the delayed inflationary effects of aggressive 2025 trade...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Healthcare Bellwether Braces for Impact: UnitedHealth Group’s High-Stakes Q4 Outlook Signals a Sector-Wide Reset

January 13, 2026

As the 44th Annual J.P. Morgan Healthcare Conference kicked off this week in San Francisco, all eyes turned to UnitedHealth Group (NYSE:UNH), the diversified healthcare giant that serves as the primary...

Via MarketMinute

Topics Earnings Economy Stocks

1 Momentum Stock with Impressive Fundamentals and 2 Facing Challenges

January 11, 2026

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.

Via StockStory

Topics Bonds

This ETF Is Proof That the Healthcare Rebound Is Real ↗

January 11, 2026

Via MarketBeat

Topics ETFs

House Approves Affordable Care Act Subsidies For Three Years In 230-196 Vote ↗

January 08, 2026

Via Stocktwits

Can These Dividend Stocks Beat the Market Again in 2026? ↗

January 08, 2026

There is an even more important question to address.

Via The Motley Fool

UnitedHealth, CVS, Molina Get 2026 Boost From ACA Premiums Rise — Mark Cuban Slams Insurers As ‘Too Big To Care’ ↗

January 07, 2026

With enhanced ACA subsidies now expired, average out-of-pocket premiums for Obamacare users are expected to more than double.

Via Stocktwits

Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List ↗

January 05, 2026

The development comes as attention remains on Hims’ longer-term business expansion initiatives.

Via Stocktwits

The GLP-1 Pricing Revolution: How Novo Nordisk and Eli Lilly Redefined the Weight-Loss Market for 2026

January 02, 2026

As the calendar turns to 2026, the landscape for weight-loss and diabetes medication has been fundamentally transformed. What began two years ago as a "wild west" of $1,000-a-month list prices and...

Via MarketMinute

Topics Economy Intellectual Property

2 Large-Cap Stocks Worth Your Attention and 1 We Question

January 01, 2026

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an...

Via StockStory

Topics Credit Cards

The Great Unbundling: How Federal Scrutiny is Dismantling the PBM Profit Machine

December 31, 2025

The long-standing dominance of Pharmacy Benefit Managers (PBMs) in the American healthcare system has reached a critical inflection point as 2025 draws to a close. For decades, these "middlemen"...

Via MarketMinute

Cigna Group (CI) Secures ‘Buy’ Upgrades as Analysts Dismiss PBM Regulatory Fears as Market Overreaction

December 31, 2025

As the curtain closes on 2025, the investment community is witnessing a significant shift in sentiment regarding the managed care sector. Cigna Group (NYSE: CI) has become the centerpiece of this...

Via MarketMinute

Topics Government Lawsuit

IGSB vs VCSH: Two Approaches to Short-Term Investment-Grade Credit ↗

December 30, 2025

Both ETFs target short-term investment-grade bonds, but their construction determines how visible credit risk becomes when spreads move.

Via The Motley Fool

Topics Bonds ETFs

3 Low-Volatility Stocks We Think Twice About

December 28, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

LQD vs VCLT: Two Ways to Hold Corporate Credit ↗

December 26, 2025

Both funds invest in investment-grade corporate bonds, but they sit in very different places on the yield curve. Over time, that distinction determines how each fund moves when interest rates shift

Via The Motley Fool

Topics Bonds ETFs Economy

3 Cash-Producing Stocks That Fall Short

December 23, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

LQD vs. VCLT: Choosing Between Stability and Long-Rate Exposure ↗

December 22, 2025

Both ETFs hold investment-grade corporate bonds, but LQD prioritizes balance while VCLT ties returns more closely to long-term rate moves

Via The Motley Fool

Topics Bonds ETFs

< Previous 1 2 3 4 5 6 7 8 9

...

72 73 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.